1.26 USD
+0.05 (+4.13%)
At close: Feb 6, 2026
1.26 USD
0 (0%)
After Hours: 2/6/2026, 8:00:01 PM
HRTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. While HRTX is still in line with the averages on profitability rating, there are concerns on its financial health. While showing a medium growth rate, HRTX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- HRTX had negative earnings in the past year.
- HRTX had a negative operating cash flow in the past year.
- In the past 5 years HRTX always reported negative net income.
- In the past 5 years HRTX always reported negative operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of -5.45%, HRTX belongs to the best of the industry, outperforming 85.90% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -91.22%, HRTX is in line with its industry, outperforming 48.38% of the companies in the same industry.
- HRTX has a Return On Invested Capital of 0.79%. This is amongst the best in the industry. HRTX outperforms 88.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.45% | ||
| ROE | -91.22% | ||
| ROIC | 0.79% |
ROA(3y)-42.67%
ROA(5y)-52.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Operating Margin value of 1.03%, HRTX belongs to the best of the industry, outperforming 88.95% of the companies in the same industry.
- HRTX's Gross Margin of 73.92% is amongst the best of the industry. HRTX outperforms 83.24% of its industry peers.
- In the last couple of years the Gross Margin of HRTX has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.03% | ||
| PM (TTM) | N/A | ||
| GM | 73.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.17%
GM growth 5Y4.86%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HRTX is destroying value.
- HRTX has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, HRTX has more shares outstanding
- The debt/assets ratio for HRTX has been reduced compared to a year ago.
2.2 Solvency
- HRTX has an Altman-Z score of -8.98. This is a bad value and indicates that HRTX is not financially healthy and even has some risk of bankruptcy.
- HRTX has a worse Altman-Z score (-8.98) than 69.33% of its industry peers.
- HRTX has a Debt/Equity ratio of 2.16. This is a high value indicating a heavy dependency on external financing.
- HRTX has a Debt to Equity ratio of 2.16. This is in the lower half of the industry: HRTX underperforms 78.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.16 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.98 |
ROIC/WACC0.07
WACC10.61%
2.3 Liquidity
- A Current Ratio of 2.56 indicates that HRTX has no problem at all paying its short term obligations.
- With a Current ratio value of 2.56, HRTX is not doing good in the industry: 69.52% of the companies in the same industry are doing better.
- A Quick Ratio of 1.78 indicates that HRTX should not have too much problems paying its short term obligations.
- The Quick ratio of HRTX (1.78) is worse than 76.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.56 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 83.33% over the past year.
- HRTX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.60%.
- The Revenue has been decreasing by -0.24% on average over the past years.
EPS 1Y (TTM)83.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y18.69%
Revenue growth 5Y-0.24%
Sales Q2Q%16.47%
3.2 Future
- The Earnings Per Share is expected to grow by 45.81% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 14.66% on average over the next years. This is quite good.
EPS Next Y22.37%
EPS Next 2Y34.44%
EPS Next 3Y52.67%
EPS Next 5Y45.81%
Revenue Next Year9.43%
Revenue Next 2Y10.5%
Revenue Next 3Y12.5%
Revenue Next 5Y14.66%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- HRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year HRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, HRTX is valued cheaply inside the industry as 91.05% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 49.38 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as HRTX's earnings are expected to grow with 52.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.44%
EPS Next 3Y52.67%
5. Dividend
5.1 Amount
- HRTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.26
+0.05 (+4.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners84.11%
Inst Owner Change-1.06%
Ins Owners0.61%
Ins Owner Change14.48%
Market Cap231.03M
Revenue(TTM)155.10M
Net Income(TTM)-13.58M
Analysts84
Price Target4.59 (264.29%)
Short Float %19.53%
Short Ratio19.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-128.76%
Min EPS beat(2)-161.44%
Max EPS beat(2)-96.08%
EPS beat(4)2
Avg EPS beat(4)40.75%
Min EPS beat(4)-161.44%
Max EPS beat(4)246.99%
EPS beat(8)5
Avg EPS beat(8)33%
EPS beat(12)7
Avg EPS beat(12)22.59%
EPS beat(16)9
Avg EPS beat(16)15.22%
Revenue beat(2)0
Avg Revenue beat(2)-4.12%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-4.02%
Revenue beat(4)2
Avg Revenue beat(4)0.17%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)7%
Revenue beat(8)4
Avg Revenue beat(8)-0.3%
Revenue beat(12)5
Avg Revenue beat(12)-0.21%
Revenue beat(16)7
Avg Revenue beat(16)-1.01%
PT rev (1m)0%
PT rev (3m)-5.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-128.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.49 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 15.52 | ||
| P/tB | 15.52 | ||
| EV/EBITDA | 49.38 |
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.85
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.45% | ||
| ROE | -91.22% | ||
| ROCE | 1% | ||
| ROIC | 0.79% | ||
| ROICexc | 1.22% | ||
| ROICexgc | 1.22% | ||
| OM | 1.03% | ||
| PM (TTM) | N/A | ||
| GM | 73.92% | ||
| FCFM | N/A |
ROA(3y)-42.67%
ROA(5y)-52.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.17%
GM growth 5Y4.86%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.16 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 8.14 | ||
| Cap/Depr | 40.5% | ||
| Cap/Sales | 0.62% | ||
| Interest Coverage | 0.28 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.56 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | -8.98 |
F-Score4
WACC10.61%
ROIC/WACC0.07
Cap/Depr(3y)61.69%
Cap/Depr(5y)104.8%
Cap/Sales(3y)1.37%
Cap/Sales(5y)3.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y22.37%
EPS Next 2Y34.44%
EPS Next 3Y52.67%
EPS Next 5Y45.81%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y18.69%
Revenue growth 5Y-0.24%
Sales Q2Q%16.47%
Revenue Next Year9.43%
Revenue Next 2Y10.5%
Revenue Next 3Y12.5%
Revenue Next 5Y14.66%
EBIT growth 1Y106.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y69.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.44%
OCF growth 3YN/A
OCF growth 5YN/A
HERON THERAPEUTICS INC / HRTX FAQ
What is the ChartMill fundamental rating of HERON THERAPEUTICS INC (HRTX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to HRTX.
What is the valuation status of HERON THERAPEUTICS INC (HRTX) stock?
ChartMill assigns a valuation rating of 2 / 10 to HERON THERAPEUTICS INC (HRTX). This can be considered as Overvalued.
What is the profitability of HRTX stock?
HERON THERAPEUTICS INC (HRTX) has a profitability rating of 4 / 10.
What is the financial health of HERON THERAPEUTICS INC (HRTX) stock?
The financial health rating of HERON THERAPEUTICS INC (HRTX) is 2 / 10.